Supplements to Support Heart Health

An FDA-approved GLP-1 receptor agonist (Ozempic/Rybelsus for type 2 diabetes, Wegovy for chronic weight management) with genuinely strong, large-RCT evidence for glycemic control and substantial weight loss, plus a cardiovascular-outcomes benefit. Honest appraisal: this is a real prescription medicine with real efficacy AND real risks — a boxed warning for thyroid C-cell tumors, pancreatitis and gallbladder risk, very common GI side effects, and growing concern about grey-market/compounded versions. It is included here for reference only, not as a supplement and not auto-recommended.

An FDA-approved once-weekly GLP-1 receptor agonist (brand Trulicity) for type 2 diabetes, with genuinely strong, large-RCT evidence for lowering HbA1c plus a dedicated cardiovascular-outcomes trial (REWIND) showing a ~12% reduction in major cardiovascular events. Honest appraisal: this is a real prescription medicine with real efficacy AND real risks — a boxed warning for thyroid C-cell tumors, pancreatitis and gallbladder risk, very common GI side effects, and modest (not semaglutide-tier) weight loss. It is included here for reference only, not as a supplement and not auto-recommended.

An FDA-approved, once-daily GLP-1 receptor agonist (Victoza for type 2 diabetes, Saxenda for chronic weight management). Honest appraisal: a real prescription medicine with genuinely strong large-RCT evidence for glycemic control and moderate weight loss, plus a cardiovascular-outcomes benefit (LEADER). It also carries real risks — a boxed warning for thyroid C-cell tumors, pancreatitis and gallbladder risk, very common GI side effects, and lean-mass loss with weight loss. Included here for reference only; it is NOT a supplement and is not auto-recommended.

An investigational once-weekly injectable, exendin-based (exenatide-lineage) GLP-1 receptor agonist most famous for the AMPLITUDE-O cardiovascular-outcomes trial — the first to show that an EXENDIN-based (rather than human-GLP-1-based) agonist reduces major adverse cardiovascular events AND kidney-outcome events in high-risk type 2 diabetes. Honest framing: in AMPLITUDE-O (NEJM 2021, n=4,076) efpeglenatide cut MACE by ~27% and a composite kidney outcome by ~32% versus placebo, and across its phase-2/3 program it lowered HbA1c (up to ~1.0-1.2%) and bodyweight (placebo-adjusted up to ~7 kg in obesity without diabetes). BUT it is INVESTIGATIONAL and not FDA-approved or marketed anywhere; the proven benefits are metabolic and cardiorenal (HbA1c, weight, MACE, kidney) — NOT a demonstrated lifespan/longevity outcome. It carries the full GLP-1-class GI side-effect burden (very common dose-dependent nausea, vomiting, diarrhea). It is a prescription-pathway investigational drug, not a dietary supplement, and grey-market 'efpeglenatide' is especially risky.

A fully human monoclonal-antibody PCSK9 inhibitor (Praluent), injected under the skin every 2 weeks, that lowers LDL cholesterol by ~50–60%. In the ODYSSEY OUTCOMES trial of ~18,900 post-heart-attack patients it reduced major cardiovascular events and showed a possible all-cause mortality signal. Generally well tolerated; injection-site reactions and high cost/access are the main trade-offs. Prescription drug, not a supplement.

A prescription PCSK9-inhibitor monoclonal antibody (Repatha) given by subcutaneous injection. By binding circulating PCSK9 it spares LDL receptors and lowers LDL cholesterol by roughly 60%. The landmark FOURIER trial in ~27,500 statin-treated patients showed it cut cardiovascular events, and it produces dramatic LDL lowering in familial hypercholesterolemia. Very safe apart from injection-site reactions; cost and injection burden are the main trade-offs. A prescription drug, not a supplement.

A prescription oral statin (Crestor) that inhibits HMG-CoA reductase, the rate-limiting enzyme of cholesterol synthesis — one of the most potent statins, lowering LDL-C ~45–55%. In JUPITER (~17,800 people with elevated hsCRP), rosuvastatin cut major cardiovascular events and all-cause mortality; IVUS trials (ASTEROID, SATURN) show coronary plaque regression. Risks: myalgia, rare rhabdomyolysis, a small new-onset-diabetes signal, and transient liver-enzyme rise. Prescription drug, not a supplement.

An FDA-approved oral LDL-cholesterol-lowering drug (Nexletol) that inhibits ATP-citrate lyase (ACL) upstream of statins in the cholesterol-synthesis pathway. Because it is a prodrug activated in the liver — not muscle — it largely avoids statin-type muscle pain, making it a key option for statin-intolerant patients. The landmark CLEAR Outcomes RCT (~14,000 patients) showed reduced major cardiovascular events. Lowers LDL-C ~15-25% as monotherapy. Raises uric acid (gout), liver enzymes, and carries a small tendon-rupture signal. Prescription drug, not a supplement.

An SGLT2-inhibitor diabetes drug (Farxiga/Forxiga) with broad, robust human outcome evidence — it cuts heart-failure hospitalization and cardiovascular death across the ejection-fraction spectrum and slows kidney-disease progression, including in non-diabetics. The sibling of empagliflozin, used off-label for 'longevity,' though longevity itself is unproven (the lifespan data are for sibling canagliflozin in mice). A prescription drug, not a supplement.

An SGLT2-inhibitor diabetes drug (Jardiance) with the strongest human outcome evidence of its class — it cuts cardiovascular death, heart-failure hospitalization, and kidney-disease progression even in non-diabetics. The most widely used SGLT2 for off-label 'longevity,' though longevity itself is unproven (the lifespan data are for sibling canagliflozin in mice). A prescription drug, not a supplement.

A prescription, highly-purified ethyl ester of EPA (Vascepa) — NOT a fish-oil supplement. At 4 g/day it lowers triglycerides and, in the REDUCE-IT trial of statin-treated high-risk patients, cut major cardiovascular events ~25%. Honest caveats: the mechanism of benefit is debated (the trial's mineral-oil comparator may have inflated the effect), it modestly raises atrial fibrillation and bleeding risk, and OTC omega-3/fish-oil supplements did NOT show the same benefit. Prescription drug, not a supplement.

An SGLT2-inhibitor diabetes drug (Invokana) that lowers glucose by excreting it in urine. It extended lifespan in male mice in the NIA aging program, and the SGLT2 class has strong proven cardiovascular, kidney, and heart-failure benefits in humans. Longevity benefit itself is unproven; carries genital-infection and (rarely) ketoacidosis risks. Prescription drug, not a supplement.

A small interfering RNA (siRNA) prescription drug (Leqvio) that silences PCSK9 in the liver, cutting LDL cholesterol ~50%. Distinctive for being dosed by subcutaneous injection only twice a year after the first doses — a major adherence advantage. LDL lowering is well established (ORION-9/-10/-11); cardiovascular-outcome benefit is NOT yet proven (ORION-4/VICTORION trials ongoing). Prescription drug, not a supplement.

A prescription oral cholesterol-absorption inhibitor (Zetia) that blocks the intestinal NPC1L1 sterol transporter, lowering LDL-C ~15–20% on its own and more when added to a statin. In IMPROVE-IT (~18,000 post-ACS patients) ezetimibe added to simvastatin cut cardiovascular events — the first proof a non-statin LDL-lowering drug improves outcomes. Very well tolerated; rare myalgia and small liver-enzyme rise. Prescription drug, not a supplement.

An angiotensin-receptor blocker (Cozaar) — a first-line blood-pressure drug with proven human stroke-prevention and diabetic-kidney-protection outcomes. Its longevity/geroscience interest is the renin-angiotensin–aging axis plus a striking ANIMAL story: blocking the AT1 receptor dampens TGF-β signaling and restores muscle repair in aged/sarcopenic mice. But the anti-sarcopenia and lifespan benefits remain animal-only — not demonstrated in humans. A prescription drug used off-label, not a supplement.

An angiotensin-receptor blocker (Micardis) that is unusual among RAS drugs for also being a partial PPARγ agonist — the receptor that glitazone diabetes drugs target. That dual action gives it a metabolic edge: across head-to-head RCTs and a meta-analysis it improves insulin sensitivity, glucose, and lipids more than other ARBs, which is why it features in geroscience discussions. But it is an approved blood-pressure drug whose proven outcomes are cardiovascular, not a demonstrated lifespan/healthspan benefit — and its own pivotal trials show no superiority over ramipril (ONTARGET) and no recurrent-stroke reduction (PRoFESS). A prescription drug, not a supplement.

An injectable anti-interleukin-1β monoclonal antibody (Ilaris), approved for rare periodic fever syndromes. Famous for the landmark CANTOS trial — the first proof that lowering inflammation alone (without touching lipids) cuts cardiovascular events, validating the 'inflammaging' hypothesis. But CANTOS showed NO all-cause-mortality benefit and MORE fatal infections, and the follow-up cancer trials failed. An extremely expensive prescription biologic, not a supplement.

An ACE-inhibitor blood-pressure/heart drug studied as a geroprotector by targeting the renin-angiotensin system. ACE inhibition extends lifespan in C. elegans (and captopril specifically modulates a worm aging pathway), and the class has decades of human cardiovascular/kidney-protective evidence — but human longevity itself is unproven. A prescription drug used off-label, not a supplement.

An ancient anti-inflammatory drug (from autumn crocus) for gout and familial Mediterranean fever, now studied as a geroprotector targeting 'inflammaging.' Randomized trials (LoDoCo2, COLCOT) show low-dose colchicine reduces cardiovascular events in coronary disease — proof that dampening chronic inflammation has real outcome benefit. Lifespan itself is unproven. A prescription drug used off-label, not a supplement.

A decades-old non-dihydropyridine calcium-channel blocker for hypertension, angina, and arrhythmia, being repurposed to PRESERVE pancreatic beta-cell function in new-onset type-1 diabetes. Two randomized trials (adults — Nature Medicine 2018; children/adolescents — JAMA 2023, CLVer) show it partially preserves C-peptide. The benefit is partial and adjunctive — not a cure, and it wanes after stopping. A prescription drug, not a supplement.

An oral thiazolidinedione (Actos) diabetes drug that improves insulin sensitivity via PPAR-gamma. It drew geroscience interest after reducing recurrent stroke/MI in insulin-resistant non-diabetics (IRIS) and improving NASH liver histology — but weight gain, fluid retention / heart-failure risk, fracture risk, and a debated bladder-cancer signal keep enthusiasm in check. Prescription drug, not a supplement.

An oral diabetes drug (alpha-glucosidase inhibitor) that blunts post-meal glucose spikes. It robustly extended lifespan in male mice in the NIA aging program and reduced cardiovascular events in human prevention trials. Human longevity benefit is unproven; the main downside is gas/GI side effects. A prescription drug taken off-label, not a supplement.

The classic geroprotector candidate that was properly tested — and largely failed. The large ASPREE trial found daily low-dose aspirin did NOT extend disability-free survival in healthy older adults and was associated with more bleeding (and numerically higher mortality). It retains real value in secondary cardiovascular prevention, but for healthy-aging/primary prevention the evidence is negative. A medical drug, not a supplement.